[SCHEDULE 13G/A] Ligand Pharmaceuticals Inc. SEC Filing
Janus Henderson Group plc reports a significant passive holding in Ligand Pharmaceuticals common stock, totaling 1,060,734 shares (5.5% of the class). The filing identifies Janus Henderson indirect subsidiaries, with JHIUS reported as beneficial owner of 990,102 shares (5.1%), and indicates these positions are managed by registered investment adviser subsidiaries for managed portfolios. The filer certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Janus Henderson Group plc segnala una partecipazione passiva significativa nelle azioni ordinarie di Ligand Pharmaceuticals, per un totale di 1.060.734 azioni (5,5% della classe). Il deposito identifica societ脿 controllate indirette di Janus Henderson, con JHIUS indicata come proprietaria beneficiaria di 990.102 azioni (5,1%), e specifica che tali posizioni sono gestite da societ脿 sussidiarie registrate come consulenti d'investimento per portafogli gestiti. Il dichiarante certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinario svolgimento dell'attivit脿 e non allo scopo di modificare o influenzare il controllo dell'emittente.
Janus Henderson Group plc informa de una participaci贸n pasiva significativa en las acciones ordinarias de Ligand Pharmaceuticals, que asciende a 1.060.734 acciones (5,5% de la clase). La documentaci贸n identifica filiales indirectas de Janus Henderson, indicando que JHIUS figura como titular beneficiario de 990.102 acciones (5,1%), y se帽ala que estas posiciones son gestionadas por filiales asesoras de inversi贸n registradas para carteras gestionadas. El declarante certifica que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Janus Henderson Group plc電� Ligand Pharmaceuticals 氤错喌欤检棎 雽�頃� 齑� 1,060,734欤�(頃措嫻 膦呺鞚� 5.5%)鞐� 雼晿電� 靸侂嫻頃� 靾橂彊鞝� 氤挫湢毳� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊電� Janus Henderson鞚� 臧勳爲 鞛愴殞靷ゼ 氚濏瀳氅�, JHIUS臧� 990,102欤�(5.1%)鞚� 鞁れ 靻岇湢鞛愲 氤搓碃霅�鞚� 氇呾嫓頃橁碃, 鞚措煬頃� 韽靺橃潃 霌彪霅� 韴瀽鞛愲 鞛愴殞靷皜 鞖挫毄頃橂姅 甏�毽槙 韽姼韽措Μ鞓れ棎靹� 甏�毽悳雼り碃 鞝侅嫓頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 頃措嫻 歃濌秾鞚� 鞓侅梾鞚� 韱奠儊鞝� 氩旍渼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞚挫棎 鞓來枼鞚� 氙胳範 氇╈爜鞙茧 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Janus Henderson Group plc d茅clare une participation passive importante dans les actions ordinaires de Ligand Pharmaceuticals, totalisant 1 060 734 actions (5,5 % de la cat茅gorie). Le d茅p么t identifie des filiales indirectes de Janus Henderson, indiquant que JHIUS est d茅clar茅 propri茅taire b茅n茅ficiaire de 990 102 actions (5,1 %), et pr茅cise que ces positions sont g茅r茅es par des filiales conseill猫res en investissement agr茅茅es pour des portefeuilles g茅r茅s. Le d茅clarant certifie que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Janus Henderson Group plc meldet ein bedeutendes passives Engagement an den Stammaktien von Ligand Pharmaceuticals in H枚he von insgesamt 1.060.734 Aktien (5,5% der Klasse). Die Einreichung benennt indirekte Tochtergesellschaften von Janus Henderson, wobei JHIUS als wirtschaftlicher Eigent眉mer von 990.102 Aktien (5,1%) ausgewiesen ist, und gibt an, dass diese Positionen von registrierten Investment-Advisor-Tochtergesellschaften f眉r verwaltete Portfolios betreut werden. Der Meldende best盲tigt, dass die Wertpapiere im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle 眉ber den Emittenten dienen.
- Aggregate beneficial ownership of 1,060,734 shares representing 5.5% of the class, a material disclosure for investors
- Subsidiary disclosure identifies JHIUS as holding 990,102 shares (5.1%), clarifying allocation within the group
- Certification of passive intent (held in the ordinary course and not to influence control) consistent with a Schedule 13G filing
- None.
Insights
TL;DR: Janus Henderson discloses a >5% passive stake in LGND, signaling notable investor interest without control intent.
The filing shows an aggregate beneficial position of 1,060,734 shares (5.5%), which exceeds the 5% reporting threshold and is therefore material for disclosure. Item 4 details that an indirect subsidiary, JHIUS, holds 990,102 shares (5.1%). The certification in Item 10 explicitly states the holdings are in the ordinary course of business and not intended to influence control, consistent with a Schedule 13G passive disclosure rather than an active acquisition for governance purposes. For investors, the key takeaways are the size of the stake and the passive stance; there is no explicit operational or strategic action reported.
TL;DR: This is a routine governance disclosure of a passive >5% ownership by an investment manager and its subsidiaries.
The statement identifies Janus Henderson Group plc and its registered adviser subsidiaries as beneficial owners, and it includes a certification that the securities were not acquired to change or influence control. The presence of multiple entities (Janus Henderson and named subsidiaries such as JHIUS, JHIUKL and JHIAIFML) reflects allocation across adviser-managed portfolios rather than a single controlling investor. No governance actions, board nominations or change-in-control intentions are disclosed in the filing.
Janus Henderson Group plc segnala una partecipazione passiva significativa nelle azioni ordinarie di Ligand Pharmaceuticals, per un totale di 1.060.734 azioni (5,5% della classe). Il deposito identifica societ脿 controllate indirette di Janus Henderson, con JHIUS indicata come proprietaria beneficiaria di 990.102 azioni (5,1%), e specifica che tali posizioni sono gestite da societ脿 sussidiarie registrate come consulenti d'investimento per portafogli gestiti. Il dichiarante certifica che i titoli sono stati acquisiti e sono detenuti nell'ordinario svolgimento dell'attivit脿 e non allo scopo di modificare o influenzare il controllo dell'emittente.
Janus Henderson Group plc informa de una participaci贸n pasiva significativa en las acciones ordinarias de Ligand Pharmaceuticals, que asciende a 1.060.734 acciones (5,5% de la clase). La documentaci贸n identifica filiales indirectas de Janus Henderson, indicando que JHIUS figura como titular beneficiario de 990.102 acciones (5,1%), y se帽ala que estas posiciones son gestionadas por filiales asesoras de inversi贸n registradas para carteras gestionadas. El declarante certifica que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control del emisor.
Janus Henderson Group plc電� Ligand Pharmaceuticals 氤错喌欤检棎 雽�頃� 齑� 1,060,734欤�(頃措嫻 膦呺鞚� 5.5%)鞐� 雼晿電� 靸侂嫻頃� 靾橂彊鞝� 氤挫湢毳� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊電� Janus Henderson鞚� 臧勳爲 鞛愴殞靷ゼ 氚濏瀳氅�, JHIUS臧� 990,102欤�(5.1%)鞚� 鞁れ 靻岇湢鞛愲 氤搓碃霅�鞚� 氇呾嫓頃橁碃, 鞚措煬頃� 韽靺橃潃 霌彪霅� 韴瀽鞛愲 鞛愴殞靷皜 鞖挫毄頃橂姅 甏�毽槙 韽姼韽措Μ鞓れ棎靹� 甏�毽悳雼り碃 鞝侅嫓頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 頃措嫻 歃濌秾鞚� 鞓侅梾鞚� 韱奠儊鞝� 氩旍渼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞚挫棎 鞓來枼鞚� 氙胳範 氇╈爜鞙茧 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Janus Henderson Group plc d茅clare une participation passive importante dans les actions ordinaires de Ligand Pharmaceuticals, totalisant 1 060 734 actions (5,5 % de la cat茅gorie). Le d茅p么t identifie des filiales indirectes de Janus Henderson, indiquant que JHIUS est d茅clar茅 propri茅taire b茅n茅ficiaire de 990 102 actions (5,1 %), et pr茅cise que ces positions sont g茅r茅es par des filiales conseill猫res en investissement agr茅茅es pour des portefeuilles g茅r茅s. Le d茅clarant certifie que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Janus Henderson Group plc meldet ein bedeutendes passives Engagement an den Stammaktien von Ligand Pharmaceuticals in H枚he von insgesamt 1.060.734 Aktien (5,5% der Klasse). Die Einreichung benennt indirekte Tochtergesellschaften von Janus Henderson, wobei JHIUS als wirtschaftlicher Eigent眉mer von 990.102 Aktien (5,1%) ausgewiesen ist, und gibt an, dass diese Positionen von registrierten Investment-Advisor-Tochtergesellschaften f眉r verwaltete Portfolios betreut werden. Der Meldende best盲tigt, dass die Wertpapiere im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle 眉ber den Emittenten dienen.
FAQ
How many LGND shares does Janus Henderson report owning?
Does the filing indicate Janus Henderson intends to influence Ligand's control or management?
How many shares does the subsidiary JHIUS hold in LGND?
What form was filed to report this ownership in LGND?
Who signed the Schedule 13G/A for Janus Henderson?
